. , , ,

,,,

, , , , -,

? ? ?

, , , ; , .

. .

; , 75% .

, , , , ().

, , . , , .

, , , , . . ; . ( , , , .)

. , , . , , , [3].

. (. 1), .

1. .

,

-

/ /

- . , .

- , , . . .

: 0,7 .

0,15 ( , ).

. . ( Owen Mumford, Brook Hill, Woodstock, Oxford OX20 1TU).

, , . ( , , , ), , .

, .

, *

,

,

,

,

,

( )

* , , - .

( ), , , , ( ). .

. , , [5]. , , .

. , . .

, , ( ) ( ). . ( ).

.

, , , .

, [6]. , , , ( ).

. -2- , , . , . , .

101 . 37% , ( 5,4 ) . 15% , , [7]. , , , 10-20 30 .

, 40% , . Martin Dale Pharmaceyticals (UK) 5 10 . 10 20 .

, . . , , , , . , , , , .

. ( 1), , . . , , . , . .

, , , .

. . 26 , . , , ; , .

. , . , 140 20% , 112 (80%) . (42%). .

.

. , 50% . , , . , , 6 , , , [9]. 24 . , .

, .

. [10]. - 1511 ; 996 (66%) , . .

(65% 19%). , 7 10 . , , , , , . .

. . [11,12]. (, 3% , 0,25% 0,05% ), [13]. .

( / ) .

. . , ().

, , . . [14,15] .

1. Feldman H. A., Goldstein, Hatzichristou D. J., et al. Impotence and its medical and psychological correlates: Results of the Massachusetts male aging study. J. Urol 1994; 151:54.

2. Price D. E. Managing inpotence in diabetes. B. M. J. 1993; 307:275.

3. NIH, Consensus Development Panel of Impotence, JAMA 1993; 280:8392.

4. Goldstein I., Siroky M. B., et al. Vasculogenic impotence: Role of the pelvic steal test. J. Urol. 1982; 128:300306.

5. Bhasin S. Androgen treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 1992; 74:1221.

6. Herman J. B., Brotman A. W., Pollack M. H., et al. Fluoxetine induced sexial dysfunction. J. Clin. Psychiatry 1990; 51:25.

7. Riley A. J., Goodman R. E., Kellett J. M., et al. Double blind trial of yohimbine hydrichloride in erection inadequacy. J. Sexual Material Therapy 1989; 4:17.

8. Weiss J. N., Badiani G. H., Ravalli R., Brettschneider N. Reasons for high drop-out rate with self-injection therapy for impotence. Int. J. Impot. Res. 1994; 6:171.

9. Carson C. C. 3rd, Mino R.D. Priaprism assotiated with trazodone therapt. J. Urol. 1988; 139:369.

10. Padma-Natham H., Hellstrom W. J., Kaiser F. E., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N. Engl. J. Med. 1997; 336:17.

11. Class H., Baert L. Transcutaneous nitroglycerin therapy in the treatment of impotence. Urol. Int. 1989; 44:309 312.

12. Cavallini G. Minoxidil versus nitroglycerin: a prospective doubleblind controlled trial in transcutaneous erection facilitation for organic impotence. J. Urol. 1991; 146:50 53.

13. Gomaa, Shalaby M., Osman M., et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. B. M. J. 1996; 312:1512 1515.

14. Boolell M., Allen M., Ballard S., et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. of Inpotence Research 1996; 8:47 52.

15. Boolell M., Gepi-Attee J.,C., Gingell, Allen M. Sildenenfil, a novel effective oral therapy for male erectile dysfunction. B. J. Urol. 1996; 78:257 261.


, , , , -, ?

 

 

 

! , , , .
. , :